[Federal Register Volume 85, Number 139 (Monday, July 20, 2020)]
[Notices]
[Pages 43838-43839]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15654]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-20-20KH]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Injection Drug Use Surveillance Project to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on March 9, 2020, to obtain
comments from the public and affected agencies. CDC received one non-
substantive comment that was not related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or
[[Page 43839]]
other forms of information technology, e.g., permitting electronic
submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Injection Drug Use Surveillance Project--New--National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Injection Drug Use (IDU) Surveillance Project
(IDU-SP) is to develop a surveillance system to monitor drug use risk
and prevention behaviors and the infectious disease consequences of
high-risk drug use in 6-30 select urban and non-urban areas of the U.S.
that have been impacted by the opioid crisis. Such a surveillance
system is needed to inform prevention efforts and policy. The specific
objectives of the project are to assess the following among persons who
use drugs (i.e., via injecting and non-injecting routes of
administration) who are recruited in syringe services programs (SSPs)
and through peer-driven recruitment: (1) Drug use and sex risk
behaviors, injection risk networks, receipt of prevention services, and
barriers to prevention and care; and (2) the prevalence of HIV and
Hepatitis C (HCV) infections.
The project will involve a two-stage sampling approach. First, 6-30
SSPs will be selected to ensure geographic diversity and representation
of key program characteristics, such as syringe distribution model
(needs-based vs all other) and length in operation (<5 years, 5 years
or longer). Second, SSP clients and their drug using peers will be
recruited through a combination of random recruitment at SSP and social
network strategy to partake in a survey and HCV and HIV testing.
Clients of SSPs and their peers who meet eligibility criteria will
complete a survey using the Research Electronic Data Capture (REDCap)
system, a secure web-based application for administering online
surveys. The survey will include questions on drug use and sex risk
behaviors, risk networks, transitions from non-injection drug use to
drug injection, drug treatment history, history of drug use related
adverse health outcomes, such as overdose, experiences with law
enforcement, experiences with violence and access, HIV and HCV testing
experience, and use of prevention and health care services. Lastly,
participants will be offered anonymous HIV and HCV testing in
conjunction with the survey, which they may refuse with no effect on
participation in the survey.
Approximately 10,500 individuals will complete the eligibility
screening form. Our target population is 300 participants per site or
9,000 for up to 30 sites. We anticipate that, on average, 16.66% or
1,499 persons (for up to 30 SSPs) will not be interested in completing
a survey, yielding a maximum of 10,499 eligible participants. The total
annualized burden is 6,125 hours. There are no other costs to
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Respondent Form name respondents responses per response
respondent (hours)
----------------------------------------------------------------------------------------------------------------
Persons Screened...................... Eligibility Screening 10,499 1 5/60
Form.
Persons who give permission........... Model Project Permission 9,000 1 5/60
Form.
Eligible Participants................. IDU Survey.............. 9,000 1 30/60
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2020-15654 Filed 7-17-20; 8:45 am]
BILLING CODE 4163-18-P